Why the study?
Does initial treatment with losartan/HCTZ reduce blood pressure more than losartan monotherapy in Chinese patients with mild to moderate essential hypertension?
Does initial treatment with losartan/HCTZ reduce blood pressure more than losartan monotherapy in Chinese patients with mild to moderate essential hypertension?
Initial combination therapy with losartan/HCTZ provides greater blood pressure reduction than losartan monotherapy in Chinese patients with mild to moderate hypertension.
Answers are grounded in this paper and cite their sources.
Supports initial losartan/HCTZ over monotherapy for greater BP reduction; extends RCT evidence to Chinese patients with mild-moderate hypertension.
The antihypertensive efficacy and tolerability of losartan/hydrochlorothiazide (HCTZ) and losartan monotherapy as initial treatment were compared in a double-blind trial in Chinese patients with mild to moderate essential hypertension. Patients were randomised to initial treatment with either losartan/HCTZ (50 mg/12.5 mg) or losartan alone (50 mg). The doses were doubled after four weeks if diastolic blood pressure (SiDBP)was >90 mmHg. Both losartan/HCTZ and losartan alone significantly reduced SiDBP and SiSBP from baseline at the first measurement at 4 weeks (-10.1/-15.3 and -6.1/-6.9 mmHg, respectively; p<0.001) and at 8 weeks (-13.1/-18.5 and -8.7/-10.9 mmHg; p<0.001). The reductions with losartan/HCTZ were significantly greater than with losartan alone at weeks 4 and 8 (p<0.001). Both regimens were similarly well tolerated. In conclusion, initial therapy with losartan/HCTZ is effective and well tolerated in the treatment of Chinese patients with mild to moderate essential hypertension and produces a greater reduction in blood pressure than losartan alone.
No takes yet. Share an insight, caveat, or question.
Li et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: